HS-L1
Current Status: Phase I/II Clinical Trials
Advanced stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
The HS-System is under development for the treatment of patients with advanced stage NSCLC. We are now enrolling patients with stage IIIB/IV NSCLC in a phase I clinical trial using HS-L1, an HS-System therapeutic for the treatment of NSCLC. The trial is being conducted at the Sylvester Comprehensive Cancer Center in Miami, Florida and in conjunction with the University of Miami Miller School of Medicine. The primary endpoint of the trial is safety of the drug, with secondary endpoints including progression free survival, overall survival and immune response to the drug.
HS-L1 is an immune therapy that stimulates a patients immune system to recognize abnormal proteins that are expressed by lung cancer cells but not normal cells. The cells that are stimulated by HeatShock are known as cytotoxic T cells, and these cells are known to mediate regression and rejection of large tumors in both animals and humans.
About Non-Small Cell Lung Cancer
Lung cancer is the most common cause of cancer related death for both men and women worldwide. Although most common in people with risk factors such as cigarette smoking or a family history of the disease, lung cancer can effect anyone. According to the National Cancer Institute, in 2009 over 215,000 people will be diagnosed with lung cancer in the United States alone and over 70% of these people will die from their disease. The treatment plan for patients diagnosed with lung cancer depends upon the stage of the disease. For the vast majority of people, surgery, chemotherapy or radiation therapy will be the first line of treatment for the disease. Some patients may also be eligible to participate in promising clinical trials with drugs such as HeatShock.
Click here for more information on lung cancer.